Stocks and Investing
Stocks and Investing
Mon, March 13, 2017
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Terence Flynn Upgraded (BPMC) to Strong Buy on, Mar 13th, 2017
Terence Flynn of Goldman Sachs, Upgraded "Blueprint Medicines Corporation" (BPMC) to Strong Buy on, Mar 13th, 2017.
Terence has made no other calls on BPMC in the last 4 months.
There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, 0 agree with Terence's Rating of Hold.
This is the rating of the analyst that currently disagrees with Terence
- Andrew Berens of "Morgan Stanley" Initiated at Buy on, Wednesday, February 15th, 2017
Contributing Sources